Not provided
Not provided
Not provided
Not provided
Not provided
Termination due to continued lack of patient compliance
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
SAGE is an observational post market registry with the objective of characterizing long term outcomes after treatment of uterine fibroids with the Sonata System in real world clinical practice settings.
Patients whom have selected the CE-marked Sonata system for treatment of fibroids will be approached for study participation. Participation in the trial will consist of data collection in the form of questionnaires prior to and after the treatment at the following intervals: pre-procedure, 4 weeks, 1, 2, 3, 4 and 5 years following treatment.
The following data points will be collected: Length of stay, time to return to normal activities (Treatment Recovery Questionnaire), time to return to sexual activity (Treatment Recovery Questionnaire), change in fibroid symptom severity and quality of life (UFS-QOL), change in general health outcome (EQ-5D), work productivity and activity impairment (WPAI), subject satisfaction and overall treatment effect (Overall Treatment Effect and Satisfaction Questionnaire), pregnancy occurrence and outcome, non-medical re-intervention, adverse events related to the device/procedure.
Validated questionnaires are used where appropriate (UFS-QOL, E1-5D and WPAI). Double data entry will occur to ensure accurate capture of subject reported data. Monitoring will occur throughout the course of the trial to ensure adherence to the protocol.
As an observational trial, there are no pre-specified statistically powered endpoints.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Sonata | Women who undergo transcervical radiofrequency(RF) ablation with the Sonata System for treatment of their fibroids |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Sonata System | Device | Transcervical access for radiofrequency ablation of uterine fibroids |
|
| Measure | Description | Time Frame |
|---|---|---|
| Incidence of Pregnancy and Pregnancy Outcomes | Number of subjects with pregnancy and the number of pregnancies during the 5 year follow-up period. Outcome of each pregnancy including pregnancy outcomes, delivery route, antenatal and perinatal complications. | Up to 5 years-post procedure |
| Surgical Re-intervention for Heavy Menstrual Bleeding | Number of subjects who had surgical re-intervention to treat heavy menstrual bleeding during the 5 year follow-up period. | Up to 5 years-post procedure |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Uterine Fibroid Symptom - Quality of Life | UFS-QoL, validated fibroid specific assessment tool | Pre-procedure and up to 5 years |
| Length of Stay | Length of stay (in hours) for the treatment of fibroids with the Sonata System (which occurs at enrollment into the registry). |
Inclusion Criteria:
Exclusion Criteria:
Only women with diagnosed uterine fibroids are eligible to participate
Not provided
Women who select to have their uterine fibroids treated with the Sonata System
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Evangelisches Krankenhaus Köln-Weyertal gemeinnützige GmbH | Cologne | 50931 | Germany | |||
| Frauenklinik Universitätsklinikum Jena |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 33688276 | Derived | Christoffel L, Romer T, Schiermeier S. Transcervical Radiofrequency Ablation of Uterine Fibroids Global Registry (SAGE): Study Protocol and Preliminary Results. Med Devices (Auckl). 2021 Mar 3;14:77-84. doi: 10.2147/MDER.S301166. eCollection 2021. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D007889 | Leiomyoma |
| ID | Term |
|---|---|
| D009379 | Neoplasms, Muscle Tissue |
| D018204 | Neoplasms, Connective and Soft Tissue |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
Not provided
Not provided
Not provided
Not provided
Not provided
| From admission to hospital discharge, up to four weeks. |
| Time to Return to Normal Daily Activity | Questionnaire | First two weeks post procedure |
| Time to Return to Sexual Activity | Questionnaire | First two weeks post procedure |
| Change in General Health Outcome | EQ-5D standardized instrument for use as a measure of health outcome | Pre-procedure and up to 5 years |
| Work Productivity and Activity Impairment | Standardized instrument for assessing activity/productivity impairment, commonly used in health economics outcomes research. The tool measure impairment in percentage. | Pre-procedure and up to 5 years |
| Subject Satisfaction | Questionnaire | At 1 year post procedure and up to 5 years |
| Overall Treatment Effect | Questionnaire | At 1 year post procedure and up to 5 years |
| Jena |
| 07743 |
| Germany |
| Klinik für Frauenheilkunde und Geburtshilfe | Kempten | 87439 | Germany |
| MarienKrankenhaus Schwerte Frauenklinik | Schwerte | 58239 | Germany |
| Josephs-Hospital Warendorf | Warendorf | 48231 | Germany |
| Marien Hospital Witten | Witten | 58452 | Germany |
| Spital Oberengadin | Samedan | Switzerland |
| Addenbrookes Cambridge University Hospitals NHS Foundation Trust | Cambridge | CB2 0QQ | United Kingdom |
| Liverpool Women's NHS Foundation Trust | Liverpool | L8 7SS | United Kingdom |